Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan
{"title":"肉毒杆菌毒素相关行业向医生支付费用的趋势。","authors":"Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan","doi":"10.1089/fpsam.2023.0198","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> To evaluate trends in botulinum toxin (BTX) industry payments to physicians. <b>Methods:</b> Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. <b>Results:</b> Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8.7 million in 2019. 21.7% was paid to dermatologists, 57.5% to neurologists, 5.9% to ophthalmologists, 5.7% to otolaryngologists, and 9.1% to plastic surgeons. <b>Conclusions:</b> Growing amounts are being paid to physicians for BTX-related activities-both medical and aesthetic. Despite the variety of indications for BTX within otolaryngology, otolaryngology payments were overshadowed by other specialties, which may reflect greater BTX utilization in those specialties.</p>","PeriodicalId":48487,"journal":{"name":"Facial Plastic Surgery & Aesthetic Medicine","volume":" ","pages":"512-516"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in Botulinum Toxin-Related Industry Payments to Physicians.\",\"authors\":\"Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan\",\"doi\":\"10.1089/fpsam.2023.0198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives:</b> To evaluate trends in botulinum toxin (BTX) industry payments to physicians. <b>Methods:</b> Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. <b>Results:</b> Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8.7 million in 2019. 21.7% was paid to dermatologists, 57.5% to neurologists, 5.9% to ophthalmologists, 5.7% to otolaryngologists, and 9.1% to plastic surgeons. <b>Conclusions:</b> Growing amounts are being paid to physicians for BTX-related activities-both medical and aesthetic. Despite the variety of indications for BTX within otolaryngology, otolaryngology payments were overshadowed by other specialties, which may reflect greater BTX utilization in those specialties.</p>\",\"PeriodicalId\":48487,\"journal\":{\"name\":\"Facial Plastic Surgery & Aesthetic Medicine\",\"volume\":\" \",\"pages\":\"512-516\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Facial Plastic Surgery & Aesthetic Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/fpsam.2023.0198\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Facial Plastic Surgery & Aesthetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/fpsam.2023.0198","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Trends in Botulinum Toxin-Related Industry Payments to Physicians.
Objectives: To evaluate trends in botulinum toxin (BTX) industry payments to physicians. Methods: Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. Results: Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8.7 million in 2019. 21.7% was paid to dermatologists, 57.5% to neurologists, 5.9% to ophthalmologists, 5.7% to otolaryngologists, and 9.1% to plastic surgeons. Conclusions: Growing amounts are being paid to physicians for BTX-related activities-both medical and aesthetic. Despite the variety of indications for BTX within otolaryngology, otolaryngology payments were overshadowed by other specialties, which may reflect greater BTX utilization in those specialties.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
